Immunomedics, Inc. (IMMU)
(Delayed Data from NSDQ)
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.74 USD
-0.16 (-1.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data
by Zacks Equity Research
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Is Immunomedics (IMMU) Down 13.1% Since Last Earnings Report?
by Zacks Equity Research
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Earnings Preview: Immunomedics (IMMU) Q2 Earnings Expected to Decline
by Zacks Equity Research
Immunomedics (IMMU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
by Zacks Equity Research
A low key week for the biotech sector with regular drug approvals and pipeline updates.
Do Options Traders Know Something About Immunomedics (IMMU) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
by Zacks Equity Research
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Why Immunomedics (IMMU) Could Be Positioned for a Slump
by Zacks Equity Research
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics (IMMU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunomedics (IMMU) delivered earnings and revenue surprises of -25.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
by Zacks Equity Research
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Implied Volatility Surging for Immunomedics (IMMU) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session
by Zacks Equity Research
Immunomedics (IMMU) shares rose more than 10% in the last trading session, amid huge volumes.
Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock
by Zacks Equity Research
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.